Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 1691627
PUBLISHER: BCC Research | PRODUCT CODE: 1691627
Therapeutics for Women's Health: Technologies and Global Markets
PUBLISHED:
PAGES: 159 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The global therapeutics for women’s health technologies market is expected to grow from $61.5 billion in 2024 and is projected to reach $81.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.7% during the forecast period of 2024 to 2029.
The North American therapeutics for women’s health technologies market is expected to grow from $28.4 billion in 2024 and is projected to reach $37.4 billion by the end of 2029, at a CAGR of 5.6% during the forecast period of 2024 to 2029.
The European therapeutics for women’s health technologies market is expected to grow from $17.7 billion in 2024 and is projected to reach $23.5 billion by the end of 2029, at a CAGR of 5.8% during the forecast period of 2024 to 2029.
Report Scope
This report provides a detailed analysis of the global therapeutics for women's health technologies market, including coverage of market drivers, restraints and opportunities. It also includes analyses of this market's competitive environment and products. The report presents market estimates and forecasts for women's health therapeutics and provides market projections through 2029. For this analysis, the market is segmented by conditions related to women's health, including breast cancer, postmenopausal osteoporosis, menopause, endometriosis and polycystic ovary syndrome (PCOS), and by geographic region. The report provides company profiles of the market's leading players that feature detailed information about each company's business segments, financials, product portfolios and recent developments.
By region, the global therapeutics for women's health technologies market is segmented into North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes the U.K., Germany, Spain, France, Italy and the Rest of Europe; Asia-Pacific comprises China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. The rest of the World includes the Middle East and Africa, and South America. In the report's market estimates, 2021 and 2022 serve as historical years, 2023 as the base year, and data forecasts are given through 2029.
Report Includes
- 46 data tables and 63 additional tables
- An overview of the global market and technologies for women's health therapeutics
- Analyses of the global market trends, with sales data for 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- Study of women's diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS), including their historical background, stages, symptoms, risk factors -and genetic factors, diagnosis, and treatment options
- Discussion on aging and women's health disorders, women and sexual health such as female sexual arousal disorder, female orgasmic disorder and vaginismus, as well as the relationship between infertility and cancer
- Information about significant products, companies, issues and trends affecting the women's disorders and diseases industry
- Evaluation of the impact of demographic, economic and other factors that will drive demand in the market for women's health therapeutics
- Coverage of regulatory structure, pricing, and reimbursement scenarios; marketed and pipeline (R&D) products, and clinical trials
- Identification of the market drivers, restraints and other forces impacting the global market, as well as an evaluation of current and projected market size
- A discussion of ESG challenges and practices in the industry
- Market share analysis of the key companies and coverage of their proprietary technologies, strategic alliances, and other market strategies
- Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Pfizer Inc., Eli Lilly and Company, Novartis AG and Amgen Inc.
Product Code: BIO043H
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Insights
Chapter 2 Market Overview
- Overview
- Definitions
- Breast Cancer
- Postmenopausal Osteoporosis
- Menopause
- Endometriosis
- Polycystic Ovary Syndrome (PCOS)
- Historical Context
- Aging and Women's Health Disorders
Chapter 3 Market Dynamics
- Overview
- Market Drivers
- Rising Population of Older Women
- Increasing Awareness and Accessibility
- Market Restraints
- High Treatment Costs
- Regulatory Challenges
- Market Opportunities
- Advances in Personalized Medicine
- Emerging Markets
Chapter 4 Emerging Technologies
- Overview
- Digital Health Solutions
- Advanced Fertility Technologies
- Targeted Biologics and Biosimilars
- Nanotechnology-Driven Drug Delivery
- Gene Therapy and CRISPR
Chapter 5 Pipeline Assessment and Analysis
- Overview
- Women's Health Therapeutics: Key Clinical Trial Developments
- Drugs in Pipeline
- Overview of Osteoporosis Drug Development Pipeline
Chapter 6 Regulatory Structure
- Overview of Regulations
- U.S.
- Drug Development and Approval Process
- Types of Applications Reviewed by FDA
- Canada
- Food and Drugs Act (F-27)
- Europe
- Japan
Chapter 7 Market Segmentation Analysis
- Segmentation Breakdown
- Market Analysis, by Women's Health Disorder
- Breast Cancer
- Postmenopausal Osteoporosis
- Menopause
- Endometriosis
- PCOS
- Geographic Breakdown
- Market Analysis, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 8 Competitive Landscape
- Overview
- Market Players and Strategies
- Patent Analysis
- Key Developments
Chapter 9 ESG Perspective
- Introduction to ESG
- ESG Goals for the Pharmaceutical Sector
- Focus on Energy Efficiency
- Reduce Emissions and Carbon Footprint
- Waste Generation and Disposal
- Manufacturing, Distribution and Transportation
- Social Responsibility
- Governance
- ESG Risk Ratings in the Pharmaceutical Industry
- Concluding Remarks from BCC Research
Chapter 10 Appendix
- Methodology
- Sources
- Abbreviations
- Company Profiles
- ABBVIE INC.
- AMGEN INC.
- ASAHI KASEI CORP.
- ASTRAZENECA
- BAYER AG
- BRISTOL-MYERS SQUIBB CO.
- EISAI CO. LTD.
- F. HOFFMANN-LA ROCHE LTD.
- JOHNSON & JOHNSON SERVICES INC.
- LILLY
- MERCK & CO. INC.
- NOVARTIS AG
- NOVO NORDISK A/S
- PFIZER INC.
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
Product Code: BIO043H
List of Tables
- Summary Table : Global Therapeutics for Women's Health Technologies Market, by Region, Through 2029
- Table 1 : Significant Events in Women's Health History in the U.S., 1983-Post-2000
- Table 2 : Key Clinical Trial Developments, 2024
- Table 3 : Novel Breast Cancer Drug Approvals, 2020
- Table 4 : Pipeline Drugs for Treating Endometriosis
- Table 5 : Pipeline Drugs for Treating Uterine Fibroids
- Table 6 : Pipeline Drugs for Treating Osteoporosis
- Table 7 : Key European Regulations and Directives Impacting Women's Health
- Table 8 : Global Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 9 : Factors That Increase the Relative Risk for Invasive Breast Cancer in Women
- Table 10 : TNM Classification of Breast Cancers
- Table 11 : Drugs Commonly Used to Treat Breast Cancer
- Table 12 : Global Breast Cancer Market in Therapeutics for Women's Health, by Region, Through 2029
- Table 13 : Global Postmenopausal Osteoporosis Market in Therapeutics for Women's Health, by Region, Through 2029
- Table 14 : FDA-Approved Estrogen-Only Medicines
- Table 15 : FDA-Approved Progestin-Only Medicines
- Table 16 : FDA Approved Combination, Estrogen and Progestin Medicines
- Table 17 : FDA-Approved Combination Estrogen and Hormone Medicines
- Table 18 : Global Menopause Market in Therapeutics for Women's Health, by Region, Through 2029
- Table 19 : Global Endometriosis Market in Therapeutics for Women's Health, by Region, Through 2029
- Table 20 : Commonly Prescribed Generic Drugs for the Treatment of PCOS
- Table 21 : Global PCOS Market in Therapeutics for Women's Health, by Region, Through 2029
- Table 22 : Global Therapeutics for Women's Health Technologies Market, by Region, Through 2029
- Table 23 : North American Therapeutics for Women's Health Technologies Market, by Country, Through 2029
- Table 24 : North American Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 25 : U.S. Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 26 : Canadian Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 27 : Mexican Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 28 : European Therapeutics for Women's Health Technologies Market, by Country, Through 2029
- Table 29 : European Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 30 : German Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 31 : U.K. Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 32 : French Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 33 : Italian Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 34 : Spanish Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 35 : Rest of European Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 36 : Asia-Pacific Therapeutics for Women's Health Technologies Market, by Country, Through 2029
- Table 37 : Asia-Pacific Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 38 : Chinese Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 39 : Japanese Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 40 : Indian Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 41 : Australian Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 42 : South Korean Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 43 : Rest of APAC Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 44 : Rest of the World Therapeutics for Women's Health Technologies Market, by Women's Health Disorder, Through 2029
- Table 45 : Leading Companies in Therapeutics for Women's Health Technologies, 2023
- Table 46 : Major Women's Health Therapeutics Pharmaceuticals, 2023
- Table 47 : Active Patents of Key Competitor Companies, 2024
- Table 48 : Approvals for Novel Drugs for Therapeutics for Women's Health Technologies, 2021
- Table 49 : Selected New Women's Health Therapeutic Drugs in Late Stages of Clinical Development
- Table 50 : ESG Rankings for Leading Players in Therapeutics for Women's Health Technologies Market, 2024
- Table 51 : Information Sources in This Report
- Table 52 : Glossary of Terms Used in the DNA Sequencing Market
- Table 53 : AbbVie Inc.: Company Snapshot
- Table 54 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
- Table 55 : AbbVie Inc.: Product Portfolio
- Table 56 : AbbVie Inc.: News/Key Developments, 2022
- Table 57 : Amgen Inc.: Company Snapshot
- Table 58 : Amgen Inc.: Financial Performance, FY 2022 and 2023
- Table 59 : Amgen Inc.: Product Portfolio
- Table 60 : Amgen Inc.: News/Key Developments, 2023
- Table 61 : Asahi Kasei Corp.: Company Snapshot
- Table 62 : Asahi Kasei Corp.: Financial Performance, FY 2022 and 2023
- Table 63 : Asahi Kasei Corp.: Product Portfolio
- Table 64 : AstraZeneca: Company Snapshot
- Table 65 : AstraZeneca: Financial Performance, FY 2022 and 2023
- Table 66 : AstraZeneca: Product Portfolio
- Table 67 : AstraZeneca: News/Key Developments, 2023 and 2024
- Table 68 : Bayer AG: Company Snapshot
- Table 69 : Bayer AG: Financial Performance, FY 2022 and 2023
- Table 70 : Bayer AG: Product Portfolio
- Table 71 : Bayer AG: News/Key Developments, 2024
- Table 72 : Bristol-Myers Squibb Co.: Company Snapshot
- Table 73 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
- Table 74 : Bristol-Myers Squibb Co.: Product Portfolio
- Table 75 : Eisai Co. Ltd.: Company Snapshot
- Table 76 : Eisai Co. Ltd.: Financial Performance, FY 2022 and 2023
- Table 77 : Eisai Co. Ltd.: Product Portfolio
- Table 78 : F. Hoffmann-La Roche Ltd.: Company Snapshot
- Table 79 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
- Table 80 : F. Hoffmann-La Roche Ltd.: Product Portfolio
- Table 81 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023 and 2024
- Table 82 : Johnson & Johnson Services Inc.: Company Snapshot
- Table 83 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
- Table 84 : Johnson & Johnson Services Inc.: Product Portfolio
- Table 85 : Lilly: Company Snapshot
- Table 86 : Lilly: Financial Performance, FY 2022 and 2023
- Table 87 : Lilly: Product Portfolio
- Table 88 : Lilly: News/Key Developments, 2023
- Table 89 : Merck & Co. Inc.: Company Snapshot
- Table 90 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
- Table 91 : Merck & Co. Inc.: Product Portfolio
- Table 92 : Merck & Co. Inc.: News/Key Developments, 2024
- Table 93 : Novartis AG: Company Snapshot
- Table 94 : Novartis AG: Financial Performance, FY 2022 and 2023
- Table 95 : Novartis AG: Product Portfolio
- Table 96 : Novartis AG: News/Key Developments, 2022 and 2024
- Table 97 : Novo Nordisk A/S: Company Snapshot
- Table 98 : Novo Nordisk A/S: Financial Performance, FY 2022 and 2023
- Table 99 : Novo Nordisk A/S: Product Portfolio
- Table 100 : Novo Nordisk A/S: News/Key Developments, 2022 and 2024
- Table 101 : Pfizer Inc.: Company Snapshot
- Table 102 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
- Table 103 : Pfizer Inc.: Product Portfolio
- Table 104 : Pfizer Inc.: News/Key Developments, 2022
- Table 105 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
- Table 106 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
- Table 107 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
- Table 108 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2023 and 2024
List of Figures
- Summary Figure : Global Therapeutics for Women's Health Technologies Market Shares, by Region, 2023
- Figure 1 : Snapshot of Market Dynamics
- Figure 2 : Global Therapeutics for Women's Health Technologies Market Shares, by Women's Health Disorder, 2023
- Figure 3 : Global Breast Cancer Market in Therapeutics for Women's Health Technologies, 2021-2029
- Figure 4 : Global Breast Cancer Market in Therapeutics for Women's Health, by Region, 2021-2029
- Figure 5 : Global Postmenopausal Osteoporosis Market in Therapeutics for Women's Health, 2021-2029
- Figure 6 : Global Postmenopausal Osteoporosis Market in Therapeutics for Women's Health, by Region, 2021-2029
- Figure 7 : Global Menopause Market in Therapeutics for Women's Health, 2021-2029
- Figure 8 : Global Menopause Market in Therapeutics for Women's Health, by Region, 2021-2029
- Figure 9 : Global Endometriosis Market in Therapeutics for Women's Health, 2021-2029
- Figure 10 : Global Endometriosis Market in Therapeutics for Women's Health, by Region, 2021-2029
- Figure 11 : Global PCOS Market in Therapeutics for Women's Health, 2021-2029
- Figure 12 : Global PCOS Market in Therapeutics for Women's Health, by Region, 2021-2029
- Figure 13 : Global Therapeutics for Women's Health Technologies Market Shares, by Region, 2023
- Figure 14 : Global Therapeutics for Women's Health Technologies Market, by Region, 2021-2029
- Figure 15 : North American Therapeutics for Women's Health Technologies Market Shares, by Country, 2023
- Figure 16 : U.S. Therapeutics for Women's Health Technologies Market, 2021-2029
- Figure 17 : Canadian Therapeutics for Women's Health Technologies Market, 2021-2029
- Figure 18 : Mexican Therapeutics for Women's Health Technologies Market, 2021-2029
- Figure 19 : European Therapeutics for Women's Health Technologies Market Shares, by Country, 2023
- Figure 20 : German Therapeutics for Women's Health Technologies Market, 2021-2029
- Figure 21 : U.K. Therapeutics for Women's Health Technologies Market, 2021-2029
- Figure 22 : French Therapeutics for Women's Health Technologies Market, 2021-2029
- Figure 23 : Italian Therapeutics for Women's Health Technologies Market, 2021-2029
- Figure 24 : Spanish Therapeutics for Women's Health Technologies Market, 2021-2029
- Figure 25 : Rest of European Therapeutics for Women's Health Technologies Market, 2021-2029
- Figure 26 : Asia-Pacific Therapeutics for Women's Health Technologies Market Shares, by Country, 2023
- Figure 27 : Chinese Therapeutics for Women's Health Technologies Market, 2021-2029
- Figure 28 : Japanese Therapeutics for Women's Health Technologies Market, 2021-2029
- Figure 29 : Indian Therapeutics for Women's Health Technologies Market, 2021-2029
- Figure 30 : Australian Therapeutics for Women's Health Technologies Market, 2021-2029
- Figure 31 : South Korean Therapeutics for Women's Health Technologies Market, 2021-2029
- Figure 32 : Rest of APAC Therapeutics for Women's Health Technologies Market, 2021-2029
- Figure 33 : Rest of the World Therapeutics for Women's Health Technologies Market, 2021-2029
- Figure 34 : Snapshot of ESG Pillars
- Figure 35 : Advantages of ESG for Companies
- Figure 36 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2023
- Figure 37 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2023
- Figure 38 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2023
- Figure 39 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2023
- Figure 40 : Asahi Kasei Corp.: Revenue Shares, by Business Unit, FY 2023
- Figure 41 : Asahi Kasei Corp.: Revenue Shares, by Country/Region, FY 2023
- Figure 42 : AstraZeneca: Revenue Shares, by Business Unit, FY 2023
- Figure 43 : AstraZeneca: Revenue Shares, by Country/Region, FY 2023
- Figure 44 : Bayer AG: Revenue Shares, by Business Unit, FY 2023
- Figure 45 : Bayer AG: Revenue Shares, by Country/Region, FY 2023
- Figure 46 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023
- Figure 47 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023
- Figure 48 : Eisai Co. Ltd.: Revenue Shares, by Business Unit, FY 2023
- Figure 49 : Eisai Co. Ltd.: Revenue Shares, by Country/Region, FY 2023
- Figure 50 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
- Figure 51 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
- Figure 52 : Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2023
- Figure 53 : Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2023
- Figure 54 : Lilly: Revenue Shares, by Business Unit, FY 2023
- Figure 55 : Lilly: Revenue Shares, by Country/Region, FY 2023
- Figure 56 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2023
- Figure 57 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2023
- Figure 58 : Novartis AG: Revenue Shares, by Business Unit, FY 2023
- Figure 59 : Novartis AG: Revenue Shares, by Country/Region, FY 2023
- Figure 60 : Novo Nordisk A/S: Revenue Shares, by Business Unit, FY 2023
- Figure 61 : Novo Nordisk A/S: Revenue Shares, by Country/Region, FY 2023
- Figure 62 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2023
- Figure 63 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2023
- Figure 64 : Teva Pharmaceutical Industries Ltd.: Revenue Shares, by Country/Region, FY 2023
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.